These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38941099)

  • 1. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
    Wouters OJ; McKee M; Luyten J
    JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Cost of Developing a Therapeutic Complex Medical Device in the US.
    Sertkaya A; DeVries R; Jessup A; Beleche T
    JAMA Netw Open; 2022 Sep; 5(9):e2231609. PubMed ID: 36103178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014.
    Wouters OJ; Kesselheim AS; Kuha J; Luyten J
    Value Health; 2024 Oct; 27(10):1373-1381. PubMed ID: 38977188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution of sales revenues from pharmaceutical innovation.
    Grabowski HG; Vernon J
    Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing of pharmaceuticals is becoming a major challenge for health systems.
    Morgan SG; Bathula HS; Moon S
    BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
    Proudman D; Desai U; Gomes DA; Khomenko M; Martin S; Nellesen D; Neumann U; Grabowski H
    J Med Econ; 2024; 27(1):1253-1266. PubMed ID: 39361016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.